中文摘要：

目的 观察阿托伐他汀对缺血性脑血管病患者同型半胱氨酸（Hcy）、C反应蛋白（CLRP）及颈动脉内中膜厚度（IMT）的影响.方法 将2012年2月～2013年6月入住江门市人民医院神经内科且符合入选标准的患者随机分为两组,A组40例采用201 1年缺血性脑血管疾病治疗指南常规治疗并加用每日20 mg剂量阿托伐他汀,B组40例采用常规治疗并加用每日40 mg剂量阿托伐他汀.对所有患者随访6个月,记录初诊、治疗1、3、6个月时的Hcy及CRP水平,记录初诊及治疗6个月时颈动脉IMT.结果 对于缺血性脑血管病患者合并颈动脉IMT增厚者,阿托伐他汀连续应用1个月可以明显降低Hcy、CRP水平,连续应用6个月可以降低颈动脉IMT,并且B组降低Hcy、CRP及颈动脉IMT的效果较A组更明显,差异有统计学意义（P＜0.05）,两组的药物不良反应相当.结论 阿托伐他汀可以降低缺血性脑血管病患者Hcy、CRP及颈动脉IMT,并且大剂量组的效果更明显,不良反应相当.

英文摘要：

Objective To investigate the effect of Atorvastatin on homocysteine （Hcy）,C reactive protein （CRP） and carotid artery intima-media thickness （IMT） in patients with ischemic cerebrovascular disease.Methods The patients who met the inclusion criteria at Department of Neurology in the People＇s Hospital of Jiangmen City from February 2012 to June 2013 were randomly divided into two groups,40 cases in group A （using the 2011 guidelines for the treatment of ischemic cerebral vascular disease,conventional therapy plus Atorvastatin 20 mg daily dose）,40 cases in group B （conventional therapy plus 40 mg daily dose of Atorvastatin）.All patients were followed up for 6 months,recording of newly diagnosed,treatment for 1 month,3 months and 6 months of Hcy and CRP,the newly diagnosed and treatment of 6 months of the carotid artery IMT.Results For the patients with ischemic cerebral vascular disease and with carotid artery IMT thickening,continuous application of Atorvastatin for 1 month could significantly decrease Hcy,CRP level,continuous use for 6 months could reduce the carotid artery IMT,and the effect was more significant in group B than that in group A in decreasing Hcy,CRP and artery IMT,the differences were statistically significant （P 〈 0.05）,adverse drug reactions of the two groups was quite.Conclusion Atorvastatin can reduce Hcy,CRP and carotid artery IMT in patients with ischemic cerebrovascular disease,and the effect of the large dose group is more obvious.The adverse reactions of the two groups are quite.